Profile data is unavailable for this security.
About the company
MEDIPAL HOLDINGS CORPORATION engages in the wholesale of pharmaceutical products, cosmetics and daily miscellaneous goods. The Company operates in three segments. The Ethical Pharmaceutical Wholesale segment is involved in the wholesale of pharmaceutical products, medical equipment and test reagents, the distribution and planning of specialty drugs, the construction of medical material database and others. The Cosmetics, Daily Product and General Medicine Wholesale segment is engaged in the wholesale of cosmetics, daily miscellaneous goods and general pharmaceuticals. The Veterinary Medicine and Food Processing Raw Materials Wholesale segment is engaged in the wholesale of veterinary products, food additives and food raw materials. The Company is also involved in the provision of cleaning services, the management and operation of logistics centers, the provision of manpower dispatching services and others.
- Revenue in JPY (TTM)3.30tn
- Net income in JPY28.25bn
- Incorporated1923
- Employees12.80k
- LocationMedipal Holdings Corp2-7-15, YaesuCHUO-KU 104-8461JapanJPN
- Phone+81 335175800
- Fax+81 335175028
- Websitehttps://www.medipal.co.jp/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
TAKARA BIO INC. | 66.53bn | 17.73bn | 257.60bn | 1.67k | 14.57 | 2.63 | 11.69 | 3.87 | 147.25 | 147.25 | 552.50 | 815.46 | 0.6302 | 1.17 | 5.21 | 39,933,370.00 | 16.86 | 9.94 | 19.44 | 11.16 | 69.44 | 65.37 | 26.76 | 18.17 | 3.62 | 39.33 | -- | 21.03 | 46.90 | 18.17 | 107.91 | 71.14 | 52.57 | 52.51 |
Hisamitsu Pharmaceutical Co Inc | 118.83bn | 8.93bn | 294.67bn | 2.78k | 31.26 | 1.10 | 21.74 | 2.48 | 110.68 | 110.68 | 1,471.37 | 3,133.61 | 0.3911 | 2.77 | 3.69 | 42,681,390.00 | 3.02 | 5.15 | 3.43 | 5.83 | 57.41 | 61.16 | 7.72 | 11.52 | 4.20 | -- | 0.005 | 44.97 | 4.96 | -3.81 | 4.41 | -13.89 | 5.56 | 0.6061 |
JCR Pharmaceuticals Co Ltd | 50.88bn | 14.34bn | 319.68bn | 816.00 | 21.35 | 6.01 | 22.12 | 6.28 | 115.47 | 115.47 | 409.61 | 410.13 | 0.6029 | 0.7641 | 4.98 | 62,346,810.00 | 17.01 | 11.47 | 28.71 | 16.27 | 77.85 | 73.58 | 28.21 | 20.62 | 1.17 | -- | 0.262 | 22.46 | 69.79 | 23.08 | 110.49 | 50.75 | 48.86 | 29.46 |
Alfresa Holdings Corporation | 2.60tn | 31.06bn | 355.60bn | 11.93k | 11.83 | 0.7546 | 9.19 | 0.1368 | 149.77 | 149.77 | 12,542.82 | 2,348.24 | 1.95 | 16.38 | 4.25 | 217,960,500.00 | 2.34 | 2.63 | 6.06 | 7.04 | 7.18 | 7.40 | 1.20 | 1.33 | 1.07 | -- | 0.00006 | 29.60 | -0.9494 | 0.2638 | 31.35 | 0.8209 | 4.54 | 8.45 |
Sumitomo Pharma Co Ltd | 588.72bn | 82.72bn | 409.97bn | 6.99k | 4.99 | 0.6133 | 3.74 | 0.6964 | 208.20 | 208.20 | 1,481.78 | 1,693.99 | 0.4361 | 1.60 | 3.64 | 84,258,620.00 | 5.03 | 4.10 | 6.84 | 5.97 | 72.02 | 73.85 | 11.53 | 8.67 | 1.39 | -- | 0.2654 | 21.77 | 8.54 | 6.52 | 0.3451 | 12.49 | 0.052 | 9.24 |
Santen Pharmaceutical Co Ltd | 266.80bn | 26.54bn | 430.21bn | 4.32k | 16.22 | 1.23 | 9.72 | 1.61 | 66.42 | 66.42 | 667.71 | 873.79 | 0.6217 | 2.77 | 2.75 | 61,831,750.00 | 6.19 | 6.25 | 7.55 | 7.56 | 58.34 | 60.55 | 9.95 | 10.30 | 2.03 | -- | 0.1512 | 43.85 | 6.67 | 5.99 | 192.38 | 4.60 | 30.42 | 4.24 |
ROHTO PHARMACEUTICAL CO., LTD. | 199.65bn | 21.02bn | 469.99bn | 6.87k | 21.66 | 2.55 | 16.31 | 2.35 | 183.72 | 183.72 | 1,745.16 | 1,562.98 | 0.7974 | 2.71 | 4.01 | 29,077,480.00 | 8.45 | 6.77 | 11.54 | 9.52 | 58.35 | 59.29 | 10.59 | 7.83 | 1.83 | -- | 0.1198 | 21.61 | 10.13 | 5.25 | 25.53 | 15.99 | 23.27 | 11.38 |
Medipal Holdings Corp | 3.30tn | 28.25bn | 490.27bn | 12.80k | 15.90 | 0.7812 | 9.50 | 0.1484 | 126.13 | 126.13 | 14,797.15 | 2,566.73 | 1.94 | 19.67 | 4.52 | 258,133,900.00 | 2.21 | 2.60 | 6.26 | 7.26 | 6.61 | 7.02 | 1.14 | 1.32 | 1.05 | -- | 0.0436 | 26.65 | 2.48 | 1.44 | 22.98 | 0.2824 | -12.03 | 7.26 |
Nippon Shinyaku Co., Ltd. | 137.48bn | 24.99bn | 577.47bn | 2.13k | 22.16 | 3.07 | 19.52 | 4.20 | 370.97 | 370.97 | 2,041.25 | 2,681.19 | 0.6464 | 1.36 | 3.34 | 64,698,350.00 | 11.75 | 10.19 | 13.94 | 12.06 | 63.49 | 57.69 | 18.18 | 15.32 | 3.49 | -- | 0.0148 | 30.98 | 12.82 | 6.84 | 27.87 | 16.29 | 15.49 | 18.04 |
Holder | Shares | % Held |
---|---|---|
Silchester International Investors LLPas of 26 Jul 2022 | 20.02m | 8.19% |
Nomura Asset Management Co., Ltd.as of 31 May 2022 | 7.52m | 3.08% |
The Vanguard Group, Inc.as of 08 Jul 2022 | 3.84m | 1.57% |
Norges Bank Investment Managementas of 31 Dec 2021 | 3.00m | 1.23% |
Daiwa Asset Management Co. Ltd.as of 30 Jun 2022 | 3.00m | 1.23% |
Nikko Asset Management Co., Ltd.as of 08 Jul 2022 | 2.95m | 1.21% |
Geode Capital Management LLCas of 07 Jul 2022 | 2.05m | 0.84% |
BlackRock Fund Advisorsas of 07 Jul 2022 | 1.99m | 0.81% |
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 07 Jul 2022 | 1.56m | 0.64% |
Dimensional Fund Advisors LPas of 07 Jul 2022 | 1.27m | 0.52% |